baber/WOPTO huggingface dataset:
Patent EA-001747-B1 (EA)
Title: Hydrophone module for a marine seismic cable
Inventor: CHANG WIN H
IPC: G01V1/18
Filed: 1997-12-18
Abstract: 1. A low-profile hydrophone module for a marine seismic system containing data-transmitting wires, the hydrophone module comprising: a. a block having a curved surface and a receiving surface in which an open cavity is disposed; b. a hydrophone assembly, to which lead wires attach, disposed in the cavity; c. lead wires which pass out of the cavity; d. a sound-transmitting material which fills the cavity; and e. a wire-clearance recess displaced from the open cavity along a longitudinal axis of the block to receive connections between the lead wires anal the data-transmitting wires. 2. The hydrophone module of claim 1, wherein the hydrophone assembly comprises a hydrophone and an open cell foam baffle material, the baffle material enclosing the hydrophone, the cavity is sealed around the lead wires, the sound-transmitting material is oil, and a cover sealingly affixes over the cavity. 3. The hydrophone module of claim 1, wherein the sound-transmitting material is a potting sealant. 4. The hydrophone module of claim 2, wherein the curved surface is a cylindrical surface, and wherein the block has end portions and a receiving surface through which the hydrophone assembly installs in the cavity. 5. The hydrophone module of claim 1, wherein the baffle material positions the hydrophone centrally in the cavity. 6. The hydrophone module of claim 4, wherein the hydrophone frame supports the hydrophone within the cavity. 7. A method of making a hydrophone module for a marine seismic system containing data-transmitting wires, the steps comprising: a. forming a block having a curved surface and a receiving surface in which an open cavity and a wire-clearance recess are disposed, the wire-clearance recess displaced from the open cavity along a longitudinal axis of the block; b. installing a hydrophone assembly, to which lead wires attach, in the cavity; c. passing the lead wires out of the cavity; and d. filling the cavity with a sound-transmitting material, wherein the wire-clearance recess is of sufficient size to receive connections between the lead wires and the data-transmitting wires. 8. The method of claim 7, wherein the sound-transmitting material is a potting sealant. 9. The method of claim 8, wherein prior to the filling of the cavity, the cavity is sealed around the lead wires, and, after the filling, a cover sealingly affixes over the cavity. 10. The method of claim 9, wherein the curved surface is a cylindrical surface, and wherein the block has end portions and a receiving surface through which the hydrophone assembly installs in the cavity. 11. The method of claim 7, wherein the sound transmitting material is an oil.
Patent EA-001674-B1 (EA)
Title: Salt of naphthyridine carboxylic acid derivative
Inventor: KIM AE RI
IPC: A61K31/00
Filed: 1998-03-20
Abstract: 1. 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl- 6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate. 2. 7-(3 -Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate.nH2O, wherein n is in the range of from 1 to 4. 3. A compound according to claim 2 wherein n is 1.5. 4. A compound according to claim 2 having peaks at 2~ = 8.0, 12.2 and 14.7 degree  in its X-ray diffraction pattern. 5. A compound according to claim 2 having an X-ray diffraction pattern substantially as shown in Figure 7. 6. A compound according to claim 2 wherein n is 3. 7. A compound according to claim 2 having peaks at 2~ = 7.7 and 11.8 degree  in its X-ray diffraction pattern. 8. A compound according to claim 2 having an X-ray diffraction pattern substantially as shown in Figure 6. 9. A compound according to claim 2 which has a moisture content of from 4 to 6%. 10. A compound according to claim 2 which has a moisture content of from 9 to 11%. 11. A pharmaceutical composition comprising a compound according to any one of the preceding claims, together with a pharmaceutically acceptable carrier or excipient. 12. A use of a compound according to any one of claims 1 to 10, as an active ingredient of a pharmaceutical for treating bacterial infection. 13. A method of treating bacterial infections in humans and animals which comprises administering a therapeutically effective amount of a compound according to any one of claims 1 to 10. 14. The use of a compound according to any one of claims 1 to 10 for the manufacture of a medicament for treating bacterial infection. 15. A process for the preparation of a compound according to any one of claims 1 to 10, which comprises reacting 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8  -naphthyridine-3-carboxylic acid with methanesulfonic acid and crystallizing the resulting compound from solution, and where desired or necessary, adjusting the hydration of the compound. 16. A process for the preparation of a compound according to any one of claims 2 to 10, comprising exposing 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate anhydrite or a solvate thereof to a relative humidity of at least 75%. 17. A process according to claim 16, wherein the solvate is a solvate with one or more organic solvents selected from C1-C4 haloalkanes and C1-C8 alcohols. 18. A solvate of 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate with one or more organic solvents.
Patent EA-003779-B1 (EA)
Title: Stable solid pharmaceutical composition based on paracetamol
Inventor: VITANYINE MORVAL MAGDOLNA
IPC: A61K31/165
Filed: 2000-07-28
Abstract: 1) A stable, solid pharmaceutical composition comprising as active ingredients paracetamol and drotaverine hydrochloride in a mixture with one or more organic acid or potassium sorbate as stabilizers, one or more usually used pharmaceutical auxiliary materials. 2) Composition according to claim 1, containing codeine phosphate as additional active ingredient. 3) Composition according to claims 1 and 2 containing as organic acid an organic acid, having a dissociation constant (K) of 10<-3>-10<-12>. 4) Composition according to claim 3, containing ascorbic acid or citric acid as the organic acid. 5) Composition according to claims 1 and 2 containing as filler and as disintegration facilitating vehicle starch and as glider substances stearic acid, the salts or esters of it or hydrogenated vegetable oils. 6) Composition according to claim 1, containing paracetamol and drotaverine hydrochloride as active ingredients, ascorbic acid, citric acid or potassium sorbate as stabilizer, starch as filler and as disintegration facilitating vehicle, magnesium stearate, stearic acid, hydrogenated vegetable oil or talc as glider, iron (III)-oxide or Ariavit Sunset Yellow as colouring vehicle. 7) Composition according to claims 2 containing paracetamol, drotaverine hydrochloride and codein phosphate as active ingredients, ascorbic acid, citric acid or potassium sorbate as stabilizer, starch as filler and as disintegration facilitating vehicle, magnesium stearate, stearic acid, hydrogenated vegetable oil or talc as glider, iron (III)-oxide or Ariavit Sunset Yellow as colouring vehicle and poly (vinylpyrrolidone). 8) Composition according to claim 1 characterized by that it is in the form of granulates which can be filled into capsules or compressed to tablets. 9) Process for the preparation of a composition according to claim 1 characterized by that wet granulation is used. 10) Process according to claim 9 characterized by that paracetamol, drotaverine hydrochloride, starch, pretreated starch, the stabilizer organic acid and the polyvinylpyrrolidone are mixed in dry form, then the mixture is wet-granulated, dried, assorted, mixed with the glider and the disintegration facilitating substance, and then compressed to tablets.
Patent EA-005415-B1 (EA)
Title: Pharmaceutical preparation for the treatment, prophylaxis and/or diagnosis of tumors and method for the preparation of its active component
IPC: A61K35/16
Filed: 2001-07-10
Abstract: Pharmaceutical preparation for the treatment and follow-up care of tumors that comprises the blood plasma or predetermined blood plasma components of equidae animals with pair number of fingers, preferably cattle being not endangered lethally by leucosis. The predetermined fraction is the material bovin 40 and/or bovin 300 constituting the difference detectable by electrophoresis between the lipid-free fraction taken from a cattle having leucosis an the lipid-free fraction taken from a healthy cattle. In the separation method of the required fraction the initial blood is optionally treated by an anti-coagulant and the corpuscles are separated therefrom, the plasma fraction is treated by a first organic solvent, then a surfactant material composed of fine grains is added thereto, the liquid is mixed and the lipid-free fraction bound to the grains is separated from the liquid components by centrifugation, and the separated fraction is brought again into a solution.
Patent EA-011548-B1 (EA)
Title: Novel alpha-oxygenated or alpha-thiolated carboxylic acid penethylamide derivatives
Inventor: ZELLER MARTIN
IPC: C07C237/20
Filed: 2002-11-15
Abstract: The invention relates to alpha -oxygenated or alpha -thiolated carboxylic acid phenethylamide derivatives of the general formula Iincluding the optical isomers thereof and mixtures of such isomers, wherein A is phenyl optionally substituted by one or two substituents selected from the group comprising C-C-alkyl, C-C-haloalkyl, C-C-alkenyl, C-C-alkoxy, C-C-alkylthio, halogen and cyano; X is oxygen or sulfur; Y is oxygen or sulfur; Ris hydrogen; Ris hydrogen, C-C-alkyl, C-C-alkenyl, C-C-alkynyl, Ris hydrogen, C-C-alkyl, C-C-alkenyl, C-C-alkynyl, Ris C-C-alkoxy group, C-C-alkenyloxy group, C-C-alkynyloxy group or halogen, Ris hydrogen, n is the integer from 0 to 2, Bis a bridge member -(CRR)-or-(CHRR)-Z-(CRR), wherein R, R, R, and Rindependently of each other are hydrogen or C-C-alkyl, q is the integer 2, 3 or 4, r is the integer 0, 1, 2, 3; s is the integer 1, 2 or 3, provided that (r + s) is either 1, 2 or 3, Z is -O-, -S-, NR-, -CO-, -OOC-, -COO-, -NR-CO- or -CO-NR-, Ris hydrogen or C-C-alkyl, and Bis C-C-alkylene bridge and a process for the preparation thereof. These compounds possess useful plant protecting properties and may advantageously be employed in agricultural practice for controlling or preventing the infestation of plants by phytopathogenic microorganisms, especially fungi.
Patent EA-005746-B1 (EA)
Title: Device for detecting rail deformation
IPC: G01B11/16
Filed: 2002-10-17
Abstract: The invention concerns a device for retaining a motion sensor consisting of a transmitter (2) and a receiver (3). The transmitter (2) and the receiver (3) are form-closed on the structural element (1) respectively by means of a housing (20, 30) and a retaining element (21) corresponding to the housing (20, 30) and connected thereto by a screw connection (22). Therefor, the housing (20, 30) and the retaining element (21) form a clamping connection with the structural element (1), the housing (20, 30) comprising a clamping element (23) in operative connection with the structural element (1).
Patent EA-010795-B1 (EA)
Title: Alkylation process
Inventor: GRAY ROBERT M
IPC: C07C2/60
Filed: 2005-11-15
Abstract: A system and/or process for increasing the isobutane to olefin ratio in an alkylation process/system is disclosed. The system and/or process includes provisions for charging a portion of the settler effluent as a feed to at least one reaction zone downflow from the first reaction zone of a multi-zone alkylation reactor along with a portion of the olefin feed to the multi-zone alkylation reactor.
Patent EA-015922-B1 (EA)
Title: Administration of mtor inhibitor to treat patients with cancer
Inventor: BEDROSIAN CAMILLE L
IPC: A61K31/436
Filed: 2006-11-14
Abstract: The present invention relates to a method of cancer treatment, comprising administering AP23573, the total daily dose is 2 - 80 mg during 5 consecutive days followed by 2 days without AP23573 treatment, administered during two or more consecutive weeks. According to one of the invention embodiments the AP23573 administration is divided to 2 or more portions per day. Preferably, AP23573 is administered orally. The inventive method may further comprise the administration of additional 2-300 mg of AP23573 once a week. According to the invention, wherein the cancer is a sarcoma, lymphoma, or leukemia or a cancer of the bladder, colon, brain, breast, head and neck, endometrium, lung, ovary, pancreas or prostate. The AP23573 can be administered as a monotherapy, or it can be administrated in coordination with administration of one or more other drugs for treatment of cancer or alleviating cancer effects or other drugs administered to a patient. The invention constitutes a new method for the treatment of different ranges of cancers and other diseases with the objective of providing a desirable therapeutic window for achieving clinical benefit without incurring an unacceptable level of side effects.
Patent EA-015541-B1 (EA)
Title: Sheet metal section for dry construction
Inventor: KNAUF ALFONS JEAN
IPC: E04B2/78
Filed: 2006-11-07
Abstract: The invention relates to a sheet metal section for dry construction, comprising two limb portions and a base portion that connects the limb portions, in addition to at least one reinforcement strip that is situated on one of the limb portions. The means for fixing the reinforcement strip to the limb portion are provided.
Patent EA-014606-B1 (EA)
Title: Structure for mounting a building wall frames for holding panels such as photovoltaic panels
Inventor: REYAL JEAN-PIERRE
IPC: E04D13/18
Filed: 2008-04-18
Abstract: The invention relates to a structure (1) for mounting on a building wall at least one frame (50) comprising a rectangular frame (51) including an armature (2) made of at least two mounts (3) and at least two crossbars (4) assembled so as to form at least one rectangular chassis (15) adapted for receiving a frame (50), and an attachment means of at least one frame on the armature, each mount (3) having a central web (31) along which are provided two side wings (32, 33) including recesses for receiving the crossbars (4). Each crossbar (4) has a central web (40) and side wings (41, 42) including recesses for perpendicularly contacting the mounts (3) at the intersections between the crossbars (4) and the mounts (3) so that the wings of the mounts (3) and the crossbars (4) extending at the inner periphery of the rectangular chassis (15) define a protruding edge on which a frame (50) may be attached. The invention also relates to a wall equipped with such a structure on which are mounted frames for holding panels.
Patent EA-018110-B1 (EA)
Title: Peptides with reduced dimer formation
Inventor: HAFNER RODERICK PETER
IPC: A61K39/35
Filed: 2008-08-15
Abstract: The present invention relates to peptides which are formulated or engineered to prevent or reduce the formation of dimers.
Patent EA-019025-B1 (EA)
Title: Process and plant for producing metal oxide from metal hydroxide
Inventor: MISSALLA MICHAEL
IPC: C01F7/445
Filed: 2010-01-14
Abstract: The present invention relates to the production of metal oxide from metal hydroxide, in particular from aluminum hydroxide, wherein the metal hydroxide is dried in a drying means, preheated in at least one preheating stage, and calcined to metal oxide in a fluidized-bed reactor, and wherein the metal oxide obtained then is cooled. To reduce the energy demand of a calcining plant, the metal hydroxide is cleaned in at least one filter before being dried and steam formed in the drying means is recirculated into the filter.
Patent EA-032045-B1 (EA)
Inventor: Sun tianqi
IPC: C12N15/75
Filed: 2010-08-02
Abstract: Изобретение относится к вектору, способному экспрессироваться в прокариотной клетке-хозяине, содержащему индуцируемый маннозой промотор manP или manR оперона маннозы из Bacillus subtilis, оперативно связанный с транскрипционной единицей, кодирующей гетерологичный полипептид. Также изобретение относится к прокариотной клетке-хозяину, трансформированной заявленным вектором, и ее использованию в способе получения полипептида.
Patent EA-027269-B1 (EA)
Title: Recovery of carboxylic acid from its magnesium salts by precipitation using hydrochloric acid, useful for fermentation broth work-up
Inventor: DE HAAN ANDRE BANIER
IPC: C07C59/265
Filed: 2012-08-16
Abstract: The invention provides a method for preparing a succinic acid, which method comprises the steps of providing magnesium succinate in dissolved form, as part of an aqueous solution or suspension; acidifying the magnesium succinate with hydrochloric acid (HCl), thereby obtaining a solution comprising succinic acid and magnesium chloride (MgCl); precipitating succinic acid from the solution comprising succinic acid and MgCl, thereby obtaining a succinic acid precipitate and a MgClsolution; and subjecting the MgClsolution to a thermal decomposition step at a temperature of at least 300°C, thereby decomposing the MgClto magnesium oxide (MgO) and HCl, wherein said aqueous suspension comprises magnesium succinate and insoluble biomass, and wherein at least 95 wt.% of magnesium succinate is in dissolved form. It was found that the addition of HCl to a magnesium salt of succinic acid and subsequent precipitation of succinic acid from the solution leads to a very efficient separation of succinic acid from a magnesium succinate solution.
Patent EA-028416-B1 (EA)
Title: Flour semifinished product for making bread
Inventor: SAMUJLENKO TATIANA DMITRIEVNA
IPC: A21D8/02
Filed: 2015-04-01
Abstract: The invention relates to a flour milling, food-concentrating and baking industry, in particular to the production of mass grades of bread from a mixture of rye and wheat flour. The flour semifinished product includes raw components, allowing to increase the content of protein, fiber, mineral substances, reduce the content of monosaccharides and energy value. The composition of the flour semifinished product includes medium rye flour, first grade wheat flour M 36-28 or M 36-25, extrusion rye flour, rye fermented dry malt, dry milk whey, additionally contains dry active bakery yeast, iodized salt, low-fat flaxseed flour. The flour semi-finished product can be used both in the conditions of industrial bakery production, and in small bakeries, shops of trade networks, catering enterprises and for domestic use.
Patent EA-029193-B1 (EA)
Title: Etanercept formulations exhibiting marked reduction in sub-visible particles
Inventor: MANNING MARK
IPC: A61K47/30
Filed: 2013-07-09
Abstract: The invention relates to stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, with substantial reduction in sub-visible particles, and methods of manufacture of these compositions, methods of administration, and articles of manufacture.
Patent EA-026782-B1 (EA)
Title: PYRAZOLYLBENZO[d]IMIDAZOLE DERIVATIVES
Inventor: ZDZALIK DARIA
IPC: A61K31/5377
Filed: 2014-03-07
Abstract: A compound represented by the general Formula (I), wherein hydrogen atoms shown as attached to pyrazole and benzimidazole rings are attached to one of nitrogen atoms of the pyrazole or benzimidazole ring, respectively; Rrepresents -X-Q-P, wherein X is absent or represents -CH-, -C(O)- or -C(O)NH-(CH)-, wherein k is 0, 1 or 2; Q is selected from the group consisting of Q1, Q2, Q3, Q4 and Q5; P is absent or represents straight- or branched-chain C1-C3 alkyl, -(CH)-NRRor -(CH)-C(O)-NRR, wherein l and m independently of each other represent 0, 1 or 2, with the proviso that when B in Q1 represents oxygen atom, then P is absent; and Rand Rindependently represent C1 or C2 alkyl, or Rand Rtogether with nitrogen atom to which they are both attached form a 6-membered saturated heterocyclic ring, wherein one of carbon atoms in said heterocyclic ring can be replaced with -O-, -NH- or -N(C1-C2)alkyl-; and acid addition salts thereof. The compound can be useful in the treatment of cancer diseases.
Patent EA-028354-B1 (EA)
Title: Use of type ii toxin-antitoxin system genes to genotype strains of mycobacterium tuberculosis
Inventor: ALEKSEEVA MARIJA GEORGIEVNA
IPC: C12R1/32
Filed: 2014-07-24
Abstract: The invention relates to medicine, phthisiology and medical microbiology and can be used for identifying clinically significant strains of Mycobacterium tuberculosis, including multidrug resistant and extensively drug resistant strains and also strains with altered virulence, when working with patients. The invention comprises a novel method of genotyping strains of M.tuberculosis which is based on single nucleotide polymorphism of type II toxin-antitoxin system genes of the vapBC, higAB and mazEF superfamilies. The use of proposed pairs of oligonucleotides can be viewed as a method for diagnosing isolates of M.tuberculosis when treating tuberculosis, establishing an epidemiological picture and identifying new resistance and virulence genes. The present genotyping method is not restricted to the use of the above-mentioned genes only: combinations of other toxin-antitoxin system genes for which corresponding oligonucleotides are constructed can be used. The proposed method enables the accurate and rapid gentoyping of microbacteria in PCR mode, real-time PCR mode and multilocus PCR mode with subsequent sequencing, inter alia, in the MiSeq System ("Illumina", USA) and the GS Junior System ("Roche", Switzerland).
Patent EA-035353-B1 (EA)
Title: Method for producing l-asparaginic acid and recombinant escherichia coli aspartase producer strain
Inventor: SINOLITSKY MAXIM KONSTANTINOVICH
IPC: C12N1/21
Filed: 2017-02-28
Abstract: The invention relates to biotechnology and refers to a method for producing L-aspartic acid. Recombinant Escherichia coli VKPM B-11745 strain, an aspartase producer, was designed for this purpose by introducing a recombinant plasmid containing the aspA gene under the control of lactose promoter lacUV5 into E. coli VKPM 7188 strain. Producing L-aspartic acid involves biotransformation of ammonium fumarate using a biocatalyst, produced on the basis of the recombinant E. coli VKPM B-11745 strain cells, and the purification of the target product by known methods. Free or immobilized cells of the E. coli strain are used as a biocatalyst. The recombinant E. coli strain allows to produce a high level of aspartase activity without using isopropyl thiogalactoside as an inducer in the composition of the nutrient medium.
Patent EA-037549-B1 (EA)
Title: Dietary fibre composition
Inventor: LIM YEE MAE
IPC: A23L2/38
Filed: 2015-11-26
Abstract: The invention provides a composition capable of swelling under a pH condition resembling the pH of a stomach and/or the pH of an intestine, the composition comprising glucomannan; carrageenan; xanthan gum; and a monovalent or divalent cation salt; wherein said monovalent or divalent cation salt is a potassium, rubidium, caesium, ammonium, sodium, lithium, calcium, barium, magnesium or zinc salt; and wherein said glucomannan is present in an amount of 30-50% w/w by weight of the composition, and said carrageenan is present in an amount of 15-25% w/w by weight of the composition, and said xanthan gum is present in an amount of 10-25% w/w by weight of the composition, and said monovalent or divalent cation salt is present in an amount of 10-30% w/w by weight of the composition. The composition is suitable for use in managing body weight, combating obesity, combating metabolic syndrome, promoting satiety, reducing appetite, combating diabetes, lowering blood cholesterol, lowering blood pressure, reducing postpranial glycaemia or increasing insulin sensitivity.